Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Camrelizumab - Jiangsu Hengrui Medicine

Drug Profile

Camrelizumab - Jiangsu Hengrui Medicine

Alternative Names: HR-301210; INCSHR-1210; SHR-1210

Latest Information Update: 02 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Chinese PLA General Hospital; Hangzhou Cancer Hospital; Henan Cancer Hospital; Incyte Corporation; Jiangsu Hengrui Medicine Co.; Nanjing Medical University; Peking University People's Hospital; Sun Yat-Sen University; The First Affiliated Hospital of Zhengzhou University; Tianjin Medical University Cancer Institute and Hospital; West China Hospital Sichuan University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Hodgkin's disease
  • Phase III Liver cancer; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer
  • Phase II Biliary cancer; Breast cancer; Cervical cancer; Cholangiocarcinoma; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Lung cancer; Malignant melanoma; Osteosarcoma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours; Squamous cell cancer; Urogenital cancer
  • Phase I/II Diffuse large B cell lymphoma
  • Clinical Phase Unknown Glioblastoma

Most Recent Events

  • 08 Jan 2020 Nanfang Hospital of Southern Medical University plans a phase II trial for Nasopharyngeal cancer (Metastatic disease) (IV) in February 2020 (NCT04221516)
  • 31 Dec 2019 Jiangsu HengRui Medicine initiates a phase II (CAP-BRAIN) trial in patients with brain metastases of Non-small cell lung cancer in China (NCT04211090)
  • 30 Dec 2019 Henan Cancer Hospital plans a phase I/II trial for Breast cancer (Combination therapy, First-line therapy) in January 2020 (IV) (NCT04213898)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top